Enhanced patient support services improve patient persistence with multiple sclerosis treatment

Figures & data

Figure 1 Patients remaining on subcutaneous IFN β-1a treatment over time.

Abbreviations: IFN β-1a, interferon beta-1a; NHS, National Health Service; ROI, Republic of Ireland.

Table 1 Odds of patients with MS remaining on subcutaneous IFN β-1a treatment up to Month 24 when receiving MySupport versus NHS support only

Month	Patients on treatment (n)		Odds ratio of remaining on subcutaneous IFN β-1a treatment (95% CI)	P-value
	MySupport (ROI) (n=604)	NHS only (UK) (n=2,461)a
1	604	2,461	–	–
3	594	2,357	2.62 (1.36–5.05)	0.0039
6	577	2,198	2.56 (1.70–3.84)	<0.0001
12	530	1,951	1.87 (1.44–2.43)	<0.0001
24	460	1,521	1.97 (1.61–2.42)	<0.0001

Note:

a Data on file, Merck Serono Ltd, 2013.

Abbreviations: CI, confidence interval; IFN β-1a, interferon beta-1a; MS, multiple sclerosis; NHS, National Health Service; ROI, Republic of Ireland.